United States
Tom Levato
PartnerAbout
Tom Levato has extensive experience representing investment banks, issuers, and investors in capital markets transactions, including initial public offerings, follow-on public offerings, and private placements of equity, equity-linked, and debt securities. His practice covers a wide range of industries, including life sciences, technology, cannabis, retail and consumer goods, electronic vehicles, aerospace and defense, metals and mining, mineral exploration, oil exploration and production, financial services, cryptocurrency, and business development companies.
Tom is a market leader in alternative financing transactions, including Confidentially Marketed Public Offerings (CMPOs), Registered Direct Offerings (RDs), Private Investments in Public Equity (PIPEs), and At-the-Market Offerings (ATMs).
Tom also advises public and private companies on general corporate and securities matters, including corporate governance, public company reporting, and stock exchange rules and requirements.
Areas of FocusCorporateEquity Capital MarketsLife SciencesTechnologyMining and Mineral ResourcesCannabis, Hemp and CBDFintech
Bar admissionsNew YorkNew Jersey
EXPERIENCE
- An American multinational banking division and two American multinational investment banking and financial services companies as underwriters in an equity offering for a specialty finance company
- An American multinational independent investment banking and financial services company, an American multinational investment banking division, and a Canadian multinational investment bank and financial services company as underwriters in a debt offering for an American pharmaceutical and consumer packaged goods company
- Two American multinational independent investment banking and financial services companies as initial purchasers in a debt offering for a global aesthetics device company
- An American multinational financial services firm and an American multinational independent investment banking and financial services company as underwriters in the initial public offering for an AI-enabled in-vitro diagnostics company
- An American diversified financial services firm and an American multinational independent investment banking and financial services company as underwriters in an equity offering for a public communication equipment and software company
- A Canadian investment banking subsidiary as underwriter in an equity offering for a North American graphite company
- An American multinational independent investment banking and financial services company as underwriter in an equity offering for an American biopharmaceutical company
- Two American multinational independent investment banking and financial services companies and a division of an American multinational financial services company in an equity offering for a clinical-stage pharmaceutical company
- An American multinational investment banking and financial services company, an American global investment and advisory financial services firm, and a British multinational universal bank in an equity offering for an American RNA medicines biotechnology company
- An American investment advisory services company as underwriter in an equity offering for a global medical aesthetic technology company
- An American investment banking firm and an American multinational investment banking and financial services company as underwriters in an equity offering for an American bank
- A Canadian independent investment bank and an American global financial services firm as underwriters in an equity offering for a clinical-stage life sciences company
- Two American multinational investment banking and financial services companies, an American multinational investment banking division, and a diversified financial services firm as underwriters in an equity offering for a biotechnology company
- An American bank holding company and an American investment banking and financial services firm as underwriters in an equity offering for a higher education provider
- A Canadian independent investment bank as underwriter in the initial public offering for a plant-based health-food brand
- An American investment management and wealth management bank division, an American independent investment bank, and an American multinational independent investment banking and financial services company in an equity offering for a global pharmaceutical company
- An American privately held investment banking company as underwriter in the initial public offering for a clinical-stage immuno-oncology company
- An American investment management and wealth management bank division, a diversified financial services firm, a Canadian independent investment bank, and an American global financial services firm as underwriters in the initial public offering for a biopharmaceutical company
- An American independent investment bank and a diversified financial services firm as underwriters in the initial public offering for a clinical-stage biotherapeutics company
- An American multinational independent investment banking and financial services company and an American investment banking and financial services company as underwriters in the initial public offering for a biotechnology company
- An American investment banking and financial services company and an American multinational independent investment banking and financial services company as underwriters in the initial public offering for a specialty pharmaceutical company
- An American multinational independent investment banking and financial services company and a middle-market investment bank as underwriters in the initial public offering for a clinical-stage biopharmaceutical company
- An American multinational financial services firm and an American multinational investment bank and financial services company as underwriters in an equity offering for a pharmaceutical company
- An American independent investment bank and a Canadian global investment bank division as underwriters in an equity offering for a Canadian biopharmaceutical company
- A diversified financial services firm, an American global independent investment banking advisory firm, and a Swiss multinational investment banking and financial services firm as underwriters in an equity offering for a clinical-stage biopharmaceutical company
Education
- J.D., The George Washington University Law School
with honors - B.A., Bucknell University
Media Mentions
- Mentioned, "Deal Watch: Skadden, Davis Polk, Wachtell, Cravath Lead $20B Deals, as Mega M&A Continues," The American Lawyer, November 24, 2025
Connect
Phone
+1 212 335 4545
(Work, New York)